Furthermore, PRSS1 has been identified as a key player in TME modulation which impacts high-grade serous ovarian carcinoma prognosis [39], and together with other genes within an ECM panel predicted by artificial intelligence can help to provide an accurate tool to assess the patient’s response to immunotherapy and forecast ovarian cancer prognosis [40]. This evidence concerns the gene PRSS1 and ovarian serous carcinoma.